Vassilios Aslanis

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Venues

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Vassilios Aslanis, Khalid Abd-Elaziz, Robert J Slack, Anne Brinch, Lise Gravelle, Wayne Morley, De Phung, Kimberly Herman, Ian Holyer, Karen Killerup Poulsen, Peter Dogterom, Susan Tantawi, Fredrik R Zetterberg, Brian Jacoby, Hans Schambye, Bertil Lindmark
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1). Cancer chemotherapy and pharmacology (2024)
Vassilios Aslanis, Robert J Slack, Alison C MacKinnon, Catherine McClinton, Susan Tantawi, Lise Gravelle, Ulf J Nilsson, Hakon Leffler, Ashley Brooks, Sanjeev K Khindri, Richard P Marshall, Anders Pedersen, Hans Schambye, Fredrik Zetterberg
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer chemotherapy and pharmacology 91 (3) (2023)
Vassilios Aslanis, Robert J Slack, Alison C MacKinnon, Catherine McClinton, Susan Tantawi, Lise Gravelle, Ulf J Nilsson, Hakon Leffler, Ashley Brooks, Sanjeev K Khindri, Richard P Marshall, Anders Pedersen, Hans Schambye, Fredrik Zetterberg
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer chemotherapy and pharmacology 91 (3) (2023)
Vassilios Aslanis, Robert J Slack, Alison C MacKinnon, Catherine McClinton, Susan Tantawi, Lise Gravelle, Ulf J Nilsson, Hakon Leffler, Ashley Brooks, Sanjeev K Khindri, Richard P Marshall, Anders Pedersen, Hans Schambye, Fredrik Zetterberg
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer chemotherapy and pharmacology 91 (3) (2023)
Vassilios Aslanis, Robert J Slack, Alison C MacKinnon, Catherine McClinton, Susan Tantawi, Lise Gravelle, Ulf J Nilsson, Hakon Leffler, Ashley Brooks, Sanjeev K Khindri, Richard P Marshall, Anders Pedersen, Hans Schambye, Fredrik Zetterberg
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer chemotherapy and pharmacology (2023)
Vassilios Aslanis, Robert J Slack, Alison C MacKinnon, Catherine McClinton, Susan Tantawi, Lise Gravelle, Ulf J Nilsson, Hakon Leffler, Ashley Brooks, Sanjeev K Khindri, Richard P Marshall, Anders Pedersen, Hans Schambye, Fredrik Zetterberg
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer chemotherapy and pharmacology (2023)
Vassilios Aslanis, Robert J Slack, Alison C MacKinnon, Catherine McClinton, Susan Tantawi, Lise Gravelle, Ulf J Nilsson, Hakon Leffler, Ashley Brooks, Sanjeev K Khindri, Richard P Marshall, Anders Pedersen, Hans Schambye, Fredrik Zetterberg
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer chemotherapy and pharmacology 91 (3) (2023)

Vassilios Aslanis.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Vassilios Aslanis